Covalent Modifiers

MAY 5, 2024

Giulia Alboreggia, Parima Udompholkul, Carlo Baggio, Kendall Muzzarelli, Zahra Assar, and Maurizio Pellecchia Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.4c00277 Several novel and effective cysteine targeting (Cys) covalent drugs are in clinical use. However, the target area containing a druggable Cys residue is limited. Therefore, methods for creating covalent drugs that target different residues are being looked for; examples of such ligands include those that target the resi

Research 84

Research Drugs 84

Drug Patent Watch

MAY 5, 2024

Annual Drug Patent Expirations for DUAVEE Duavee is a drug marketed by Wyeth Pharms and is included in one NDA. It is available from two suppliers.

Drugs 59

Drugs Marketing 59

Perficient: Drug Development

MAY 5, 2024

In B2B commerce, establishing a robust IT roadmap is akin to charting a course through turbulent waters. There are hundreds of permutations on how to proceed with sequencing, and your capital investment and ROI discussion is only part of the equation. Many companies find themselves unsure of whether to first implement Product Information Management (PIM) systems, Commerce Platform (ECP’s) or Order Management / Commerce Order Operations & Logistics (COOL’s!).

Compliance 52

Compliance Marketing Production Regulations 52

Drug Patent Watch

MAY 5, 2024

This chart shows the pharmaceutical companies with the most patents in Hong Kong.

Pharmaceutical Companies 101

Pharmaceutical Companies Pharmaceuticals Drugs 101

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

FDA Law Blog: Biosimilars

MAY 5, 2024

By Larry K. Houck — The Associated Press reported on Tuesday following confirmation by five anonymous individuals with knowledge that the Drug Enforcement Administration (“DEA”) is moving to reschedule marijuana from schedule I to the less stringently controlled schedule III. US poised to ease restrictions on marijuana in historic shift, but it’ll remain controlled substance (Apr. 30, 2024).

FDA 95

FDA Regulations Treatment Licensing 95